Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 655066 in ankylosing spondylitis: phase II randomized, double-blind, placebo-controlled dose-finding trial
2013-003666-13Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of risankizumab in ankylosing spondylitis (AS) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: ASAS 40 response at Week 12. Started Oct 2013; status: completed.
02
Drugs
risankizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2013-003666-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003666-13.